From Whole Blood to Dose Decisions: Managing a 3-Year, Multi-Continent Bioanalytical Program for a Phase 1a/1b Trial 

When a sponsor’s biologic program expanded from a domestic Phase 1 design into a multi-region trial spanning New Zealand, EMEA, and APAC, the bioanalytical challenge centered on keeping a fragile, time-sensitive sample chain intact across nine additional clinical sites, two outsourced processing labs, and a central analytical lab, all while data had to be ready in time for each Safety Review Committee (SRC) meeting. 

The Challenge 

Whole blood samples collected in specialty tubes had to be processed and frozen at regional labs before shipment to KCAS Bio, Kansas City (KC) for analysis, all within strict stability windows, and all timed to support SRC meetings that determined dose escalation decisions. A single missed window could delay a cohort decision, so logistics and analytics had to move in lockstep for nearly three years, across every sponsor, clinical site, processing lab, and courier involved. 

Our Approach 

• Method: Ligand-binding assay (ELISA) for total protein and PD-L1 content 
• Site qualification: Both regional processing labs were qualified, with a partial validation performed by KCAS Bio, KC to ensure the method behaved consistently no matter where a sample originated 
• Regulatory framework: Conducted per FDA bioanalytical guidance and ICH M10 (2022) 

Validation Scope 

Fit-for-purpose validation covered both analytes across a full parameter set: 

By the Numbers 

The scale of the program is best reflected in the volume of samples and shipments that had to be tracked and delivered without disrupting the dosing timeline: 

• 2,865 samples analyzed for total protein; 2,750 for PD-L1 
• 218 sample analysis runs, plus 8 reagent qualification runs 
• <2% run failure rate against acceptance criteria 
• 400+ shipments tracked from clinical sites to processing labs, plus 120+ shipments from processing labs to the analytical lab 
• ~3-year study duration, coordinated across sponsor, clinical sites, processing labs, and couriers 

The Outcome 

Despite the complexity of coordinating so many moving parts across regions, data was delivered on time for every SRC meeting, supporting dose-escalation decisions throughout the study, and ultimately contributing to successful completion of the Phase 1a/1b trial. 

In Short 

KCAS Bio handled kitting, shipping logistics, and oversight of two outsourced processing labs, while KCAS Bio, KC delivered the analytical data that kept dose-escalation decisions on schedule. What began as a domestic sample-analysis project grew into a coordinated, multi-region operation, without losing the timing precision the trial depended on. 

FAQ: 

Q: Why were separate processing labs needed if the final analysis happened at KCAS Bio, KC? 
A: Whole blood samples collected in specialty tubes had to be processed and frozen close to the clinical sites to preserve sample integrity within stability windows before the longer shipment to KCAS Bio, KC. Managing regional processing labs in APAC and EMEA kept every sample within its required stability window despite the distances involved. 

Q: How was method consistency ensured across multiple sites and labs? 
A: Both processing sites underwent formal site qualification, and KCAS Bio, KC performed a partial validation to confirm the method produced consistent results regardless of where a sample was processed, a key requirement when data from multiple locations feeds into the same dose-escalation decisions. 

Q: What made the timelines in this study particularly demanding? 
A: Data had to be ready in time for each Safety Review Committee (SRC) meeting, which determined dose escalation for every cohort. With samples moving through multiple handoffs, clinical site, processing lab, courier, analytical lab, over nearly three years, there was little room for delay at any step. 

To know more about how we can support your global programs, feel free to contact us here: